Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2023 | Percentile | Sector n |
|---|---|---|---|---|
| Chachava Clinic | Healthcare Services | 39.6% | 95th pct | 312 |
| Gagua Clinic | Healthcare Services | 20.7% | 78th pct | 312 |
| Western Regional Center… | Healthcare Services | 8.0% | 48th pct | 312 |
| Multiprofile Hospital -… | Healthcare Services | 7.4% | 46th pct | 312 |
| Israeli-Georgian Medica… | Healthcare Services | 5.8% | 41st pct | 312 |
Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2023 | Chachava Clinic | Israeli-Georgian Medica… | Multiprofile Hospital -… | Western Regional Center… | Gagua Clinic |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 87.0% | 28.8% | 78.0% | 78.1% | 83.5% |
| EBITDA Margin | 39.6% | 5.8% | 7.4% | 8.0% | 20.7% |
| EBITDAR | 11,279 | 1,634 | 1,998 | 2,341 | 5,029 |
| EBITDAR Margin | 39.6% | 5.8% | 7.7% | 9.3% | 20.7% |
| EBIT Margin | 37.0% | 5.8% | -0.2% | 0.5% | 18.0% |
| Net Profit Margin | 43.8% | 8.2% | -8.8% | -5.9% | 16.6% |
| Operating Expense % of Sales | 47.5% | 23.0% | 70.8% | 70.3% | 66.3% |
| Returns | |||||
| Return on Assets (ROA) | 22.4% | 8.4% | -12.4% | -9.0% | 20.2% |
| Return on Equity (ROE) | 24.2% | 29.5% | N/A | N/A | 24.2% |
| ROIC [EBIT / Invested Capital] | 31.4% | ||||
| 8.1% |
| -0.5% |
| 1.8% |
| 23.9% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 47.4% | 89.6% | 84.8% | 10.0% |
| Debt-to-Equity | 0.00x | 1.67x | -3.58x | -2.43x | 0.12x |
| Debt-to-EBITDA | 0.00x | 8.00x | 8.59x | 6.92x | 0.40x |
| Equity-to-Assets | 92.5% | 28.4% | -25.1% | -34.9% | 83.2% |
| Net Debt | -18,018 | 12,449 | 16,011 | 13,367 | 1,630 |
| Cash & Equivalents | 18,018 | 616 | 689 | 676 | 381 |
| Total Debt | N/A | 13,065 | 16,700 | 14,043 | 2,011 |
| Liquidity & working capital | |||||
| Current Ratio | 5.02x | 1.95x | 0.30x | 0.60x | 1.50x |
| Quick Ratio | 4.68x | 1.45x | 0.25x | 0.50x | 1.33x |
| Cash Ratio | 4.31x | 0.11x | 0.03x | 0.06x | 0.20x |
| Total Current Assets | 21,010 | 10,725 | 6,517 | 6,472 | 2,917 |
| Total Current Liabilities | 4,182 | 5,505 | 21,764 | 10,743 | 1,945 |
| Inventory | 1,451 | 2,757 | 1,112 | 1,104 | 338 |
| Trade Receivables | 1,428 | 7,352 | 4,652 | 4,638 | 2,198 |
| Trade Payables | 1,016 | 4,051 | 3,469 | 3,233 | 1,343 |
| Net Working Capital | 16,828 | 5,220 | -15,247 | -4,271 | 972 |
| Net Working Capital % of Revenue | 59.0% | 18.5% | -58.4% | -16.9% | 4.0% |
| Trade Working Capital | 1,863 | 6,058 | 2,295 | 2,509 | 1,193 |
| Trade Working Capital % of Revenue | 6.5% | 21.5% | 8.8% | 9.9% | 4.9% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 2.55x | 7.29x | 5.17x | 5.02x | 11.85x |
| Days Inventory Outstanding (DIO) | 143.1 | 50.0 | 70.6 | 72.7 | 30.8 |
| Receivables Turnover | 19.97x | 3.84x | 5.61x | 5.46x | 11.05x |
| Days Sales Outstanding (DSO) | 18.3 | 95.1 | 65.0 | 66.9 | 33.0 |
| Payables Turnover | 3.64x | 4.96x | 1.66x | 1.71x | 2.98x |
| Days Payable Outstanding (DPO) | 100.2 | 73.5 | 220.2 | 212.9 | 122.4 |
| Cash Conversion Cycle | 61.2 days | 71.6 days | -84.6 days | -73.3 days | -58.6 days |
| Asset Turnover | 0.51x | 1.02x | 1.40x | 1.53x | 1.21x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 6,493 | 2,674 | 1,508 | 2,197 | 3,538 |
| Free Cash Flow (OCF − Capex proxy) | 394 | -1,528 | 1,311 | 1,605 | 1,610 |
| Cash Conversion (OCF / EBITDA) | 57.6% | 163.6% | 77.6% | 108.2% | 70.4% |
| Dividends Declared | 105 | 0 | 699 | 524 | 1,701 |
| Dividend Payout Ratio | 0.8% | 0.0% | N/A | N/A | 42.1% |